nach oben

Erschienen in:

11.11.2022 | Original Paper

Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy

verfasst von: Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-ichi Sakata

Erschienen in: Medical Molecular Morphology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Resistance of cervical cancer to radiotherapy with concurrent chemotherapy (CCRT) results in a poor prognosis. To identify new biomarkers for predicting the treatment response and prognosis, we explored exosomal microRNA (miRNA) expression signatures associated with the outcome of cervical cancer patients treated with CCRT. Exosomes were isolated from the plasma of 45 patients prior to CCRT during 2014–2020, and miRNA analysis was performed by next-generation sequencing. At a median follow-up of 38 months, 26 patients were recurrence free, 15 patients had died of the disease, and 4 patients received salvage chemotherapy due to distant metastasis. Of the 2522 miRNAs detected, 9 (miR-148a-5p, 1915-3p, 3960, 183-5p, 196b-5p, 200c-3p, 182-5p, 374a-5p, and 431-5p) showed differential expression between the recurrence-free and recurrence groups. Patients were divided into high- and low-risk groups according to the cutoff of the miRNAs-based risk score calculated from respective expression levels. The high-risk group had significantly worse disease-specific survival than the low-risk group (p < 0.001). In addition, miR-374a-5p and miR-431-5p expression showed a weak inverse correlation with tumor-infiltrating CD8+ and FOXP3+ T cells, suggesting a potential inhibitory effect on CCRT by suppressing tumor immunity. This miRNA signature could improve non-invasive monitoring and personalized treatment for cervical cancer.

Nur mit Berechtigung zugänglich

National Cancer Comprehensive Network. NCCN Guidelines: Cervical Cancer Version 1.2020. http://www.nccn.org/ August 1 2022

Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R (2016) Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 120(3):441–446. https://doi.org/10.1016/j.radonc.2016.05.014CrossRefPubMed

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812. https://doi.org/10.1200/JCO.2008.16.4368CrossRefPubMedCentral

Someya M, Tsuchiya T, Fukushima Y, Hasegawa T, Hori M, Kitagawa M, Gocho T, Mafune S, Ikeuchi Y, Hirohashi Y, Torigoe T, Iwasaki M, Matsuura M, Saito T, Matsumoto Y, Sakata KI (2021) Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy. Med Mol Morphol 54(3):245–252. https://doi.org/10.1007/s00795-021-00290-wCrossRefPubMed

Tsuchiya T, Someya M, Takada Y, Hasegawa T, Kitagawa M, Fukushima Y, Gocho T, Hori M, Nakata K, Hirohashi Y, Torigoe T, Saito T, Sakata KI (2020) Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlenther Onkol 196(8):725–735. https://doi.org/10.1007/s00066-019-01571-1CrossRefPubMed

Simons M, Raposo G (2009) Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol 21(4):575–581. https://doi.org/10.1016/j.ceb.2009.03.007CrossRefPubMed

Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA (2015) The fusion of two worlds: Non-coding RNAs and extracellular vesicles–diagnostic and therapeutic implications (Review). Int J Oncol 46(1):17–27. https://doi.org/10.3892/ijo.2014.2712CrossRefPubMed

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233. https://doi.org/10.1016/j.cell.2009.01.002CrossRefPubMedPubMedCentral

Png KJ, Halberg N, Yoshida M, Tavazoie SF (2011) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481(7380):190–194. https://doi.org/10.1038/nature10661CrossRefPubMed

10.

Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005–1017. https://doi.org/10.1016/j.cell.2009.04.021CrossRefPubMedPubMedCentral

11.

Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682–688. https://doi.org/10.1038/nature06174CrossRefPubMed

12.

Sakata K, Matsumoto Y, Tauchi H, Satoh M, Oouchi A, Nagakura H, Koito K, Hosoi Y, Suzuki N, Komatsu K, Hareyama M (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49(1):161–167. https://doi.org/10.1016/s0360-3016(00)01352-3CrossRefPubMed

13.

Someya M, Hasegawa T, Tsuchiya T, Kitagawa M, Gocho T, Fukushima Y, Hori M, Miura K, Takada Y, Nakata K, Sakata KI (2020) Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer. J Radiat Res 61(2):265–274. https://doi.org/10.1093/jrr/rrz099CrossRefPubMedPubMedCentral

14.

Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C, Fokas E, Rödel F (2017) Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology 6(3):e1288331. https://doi.org/10.1080/2162402X.2017.1288331CrossRefPubMedPubMedCentral

15.

Someya M, Tsuchiya T, Fukushima Y, Hasegawa T, Takada Y, Hori M, Miura K, Kitagawa M, Gocho T, Hirohashi Y, Torigoe T, Iwasaki M, Matsuura M, Saito T, Sakata KI (2020) Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. Jpn J Clin Oncol 50(11):1290–1297. https://doi.org/10.1093/jjco/hyaa149CrossRefPubMed

16.

Ji R, Zhang X, Gu H, Ma J, Wen X, Zhou J, Qian H, Xu W, Qian J, Lin J (2019) miR-374a-5p: A new target for diagnosis and drug resistance therapy in gastric cancer. Mol Ther Nucleic Acids 6(18):320–331. https://doi.org/10.1016/j.omtn.2019.07.025CrossRef

17.

Zhang J, He Y, Yu Y, Chen X, Cui G, Wang W, Zhang X, Luo Y, Li J, Ren F, Ren Z, Sun R (2018) Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med 7(7):3351–3362. https://doi.org/10.1002/cam4.1576CrossRefPubMedPubMedCentral

18.

Wang Y, Zhang C, Lu W, Chen R, Yu M (2021) Establishment of a prognostic-related microRNAs risk model for glioma by bioinformatics analysis. Ann Transl Med 9(12):1022. https://doi.org/10.21037/atm-21-2402CrossRefPubMedPubMedCentral

19.

Li AL, Chung TS, Chan YN, Chen CL, Lin SC, Chiang YR, Lin CH, Chen CC, Ma N (2018) microRNA expression pattern as an ancillary prognostic signature for radiotherapy. J Transl Med 16(1):341. https://doi.org/10.1186/s12967-018-1711-4CrossRefPubMedPubMedCentral

20.

Wu K, Zhang C, Zhang C, Dai D (2020) A novel three-miRNA signature identified using bioinformatics predicts survival in Esophageal Carcinoma. Biomed Res Int 10(2020):5973082. https://doi.org/10.1155/2020/5973082CrossRef

Titel: Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy
verfasst von: Masanori Someya
Tomokazu Hasegawa
Takaaki Tsuchiya
Mio Kitagawa
Yuki Fukushima
Toshio Gocho
Shoh Mafune
Yutaro Ikeuchi
Yoh Kozuka
Masashi Idogawa
Yoshihiko Hirohashi
Toshihiko Torigoe
Masahiro Iwasaki
Motoki Matsuura
Tsuyoshi Saito
Koh-ichi Sakata
Publikationsdatum: 11.11.2022
Verlag: Springer Nature Singapore
Erschienen in: Medical Molecular Morphology / Ausgabe 1/2023
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-022-00338-5

Springer Medizin

Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy

Abstract

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology

Pathological features of biopsied myocardium in patients clinically diagnosed with peripartum cardiomyopathy

Expression of CILP-2 and DDR2 and ultrastructural changes in the articular cartilage of patients with knee osteoarthritis undergoing total knee arthroplasty: a pilot morphological study

Usefulness of SynCAM3 and cyclin D1 immunohistochemistry in distinguishing superficial CD34-positive fibroblastic tumor from its histological mimics

Retinoic acid metabolism in cancer: potential feasibility of retinoic acid metabolism blocking therapy

Effects of stretching on the basement membrane structure in the soleus muscle of Wistar rats

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren